CA2309705A1 - Diagnostic serologique de la maladie de chagas - Google Patents
Diagnostic serologique de la maladie de chagas Download PDFInfo
- Publication number
- CA2309705A1 CA2309705A1 CA002309705A CA2309705A CA2309705A1 CA 2309705 A1 CA2309705 A1 CA 2309705A1 CA 002309705 A CA002309705 A CA 002309705A CA 2309705 A CA2309705 A CA 2309705A CA 2309705 A1 CA2309705 A1 CA 2309705A1
- Authority
- CA
- Canada
- Prior art keywords
- buffer
- plates
- pbs
- test
- epex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010001935 American trypanosomiasis Diseases 0.000 title claims abstract description 22
- 208000024699 Chagas disease Diseases 0.000 title claims abstract description 22
- 238000003745 diagnosis Methods 0.000 title claims abstract description 11
- 230000000405 serological effect Effects 0.000 title description 7
- 239000000427 antigen Substances 0.000 claims abstract description 42
- 102000036639 antigens Human genes 0.000 claims abstract description 42
- 108091007433 antigens Proteins 0.000 claims abstract description 42
- 238000012360 testing method Methods 0.000 claims abstract description 30
- 238000002965 ELISA Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 241000223109 Trypanosoma cruzi Species 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims abstract description 6
- 230000000890 antigenic effect Effects 0.000 claims abstract description 4
- 239000000872 buffer Substances 0.000 claims description 23
- 244000045947 parasite Species 0.000 claims description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 12
- 229940098773 bovine serum albumin Drugs 0.000 claims description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002953 phosphate buffered saline Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 4
- 239000013642 negative control Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims description 3
- 108010052968 leupeptin Proteins 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 239000012894 fetal calf serum Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 claims description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 claims 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 2
- 102100021587 Embryonic testis differentiation protein homolog A Human genes 0.000 claims 2
- 101000898120 Homo sapiens Embryonic testis differentiation protein homolog A Proteins 0.000 claims 2
- 235000020183 skimmed milk Nutrition 0.000 claims 2
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- 230000001684 chronic effect Effects 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 238000010790 dilution Methods 0.000 abstract description 5
- 239000012895 dilution Substances 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 239000000284 extract Substances 0.000 abstract description 4
- 208000004554 Leishmaniasis Diseases 0.000 abstract description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 3
- 230000009260 cross reactivity Effects 0.000 abstract description 3
- 239000012678 infectious agent Substances 0.000 abstract description 2
- 238000009666 routine test Methods 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 241001210412 Triatominae Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000012194 insect media Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne un procédé par chimiluminescence (CL)-ELISA avec des antigènes purifiés et complexes de Trypanosoma cruzi permettant de diagnostiquer de manière spécifique et sensible la maladie de Chagas chez des patients et dans des échantillons sanguins. Les préparations utilisées sont un antigène spécifique trypomastigote (A & T) et un extrait d'épimastigote (EpEx) permettant de réguler la sensibilité. La forte sensibilité du procédé CL-ELISA permet une utilisation de quantité extrêmement petite d'antigène et une dilution de sérum dans des tests de routine de 1:2000, réduisant au minimum ainsi les réactions non spécifiques ou faux-positifs. L'utilisation de l'antigène purifié A & T élimine les réactivités croisées avec d'autres agents d'infection, détecte l'infection active et permet de surveiller la chimiothérapie chez les patients chroniques. L'utilisation de la préparation antigène EpEx ne confirme pas seulement les résultats positifs avec A & T mais suggère, lors de divergences, d'autres infections telles que la leishmaniose. Comparé à d'autres tests courants utilisés dans les banques de sang principales, le procédé CL-ELISA avec les antigènes A & T et EpEx, testé en parallèle, s'est avéré nettement plus efficace en éliminant des résultats indéterminés ou en augmentant les statistiques d'échantillons positifs diagnostiqués.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/BR1998/000006 WO1999041610A1 (fr) | 1998-02-16 | 1998-02-16 | Diagnostic serologique de la maladie de chagas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2309705A1 true CA2309705A1 (fr) | 1999-08-19 |
Family
ID=4068952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002309705A Abandoned CA2309705A1 (fr) | 1998-02-16 | 1998-02-16 | Diagnostic serologique de la maladie de chagas |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA2309705A1 (fr) |
| WO (1) | WO1999041610A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005055812A2 (fr) * | 2003-12-05 | 2005-06-23 | Ciphergen Biosystems, Inc. | Biomarqueurs seriques de la maladie de chagas |
| CN105548565B (zh) * | 2015-12-30 | 2017-08-01 | 深圳市新产业生物医学工程股份有限公司 | 一种用于检测克氏锥虫抗体的试剂盒及其制备和应用 |
-
1998
- 1998-02-16 WO PCT/BR1998/000006 patent/WO1999041610A1/fr not_active Ceased
- 1998-02-16 CA CA002309705A patent/CA2309705A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999041610A1 (fr) | 1999-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0084531B1 (fr) | Determination de virus par analyse | |
| CA2158564A1 (fr) | Recepteurs de parvovirus et methodes d'utilisation | |
| Coker-Vann et al. | Serodiagnosis of human cysticercosis using a chromatofocused antigenic preparation of Taenia solium cysticerci in an enzyme-linked immunosorbent assay (ELISA) | |
| JP3557205B2 (ja) | シャガス病アッセイ及びそれに使用される試薬 | |
| CA2071546A1 (fr) | Produit antiviral | |
| Sommerville | Rapid identification of neurotropic viruses by an immunofluorescent technique applied to cerebrospinal fluid cellular deposits | |
| US6682900B1 (en) | Serological diagnosis of Chagas' disease | |
| Sugiyama et al. | An immune adherence assay for discrimination between etiologic agents of hemorrhagic fever with renal syndrome | |
| CA2309705A1 (fr) | Diagnostic serologique de la maladie de chagas | |
| JPH03502248A (ja) | アッセイ用水性洗浄液、診断試験キット及び単純ヘルペスウイルスの測定方法 | |
| Suzuki et al. | Use of acute-stage-specific antigens of Toxoplasma gondii for serodiagnosis of acute toxoplasmosis | |
| Schaeffer et al. | Applications of immunofluorescence in public health virology | |
| Grundy et al. | An enzyme-linked immunosorbent assay for the detection of Entamoeba histolytica antigens in faecal material | |
| Ravi et al. | A reverse passive haemagglutination test for detection of Japanese encephalitis virus antigens in cerebrospinal fluid | |
| US6872396B2 (en) | Specificity in the detection of anti-rubella IGM antibodies | |
| Shetty et al. | Detection of IgG, IgA, IgM and IgE antibodies in invasive amoebiasis in endemic areas | |
| CN109891246B (zh) | 包括汉城病毒与普马拉病毒来源的重组核衣壳蛋白及汉坦病毒来源的重组糖蛋白的肾综合症出血热诊断用组合物及包括其的诊断试剂盒 | |
| Khusmith et al. | Two-site sandwich ELISA for detection of Plasmodium vivax blood stage antigens using monoclonal and polyclonal antibodies | |
| de Morales | Indirect ELISA test for malaria in blood donors | |
| Mansueto et al. | Laboratory diagnosis of boutonneuse fever by enzyme-linked immunosorbent assay | |
| RU2112245C1 (ru) | Способ и набор для обнаружения антител к вирусу лихорадки долины рифт в сыворотках животных | |
| Fortier et al. | Detection of specific antibodies to Toxoplasma gondii by a competitive enzyme immunoassay using a monoclonal antibody against the P30 antigen | |
| US5756302A (en) | Human herpesvirus 6 detection assay | |
| Ueno et al. | Serological assessment of chlamydial infection in the koala by a slide EIA technique | |
| CN1150649A (zh) | 一种莱姆病酶联免疫诊断试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |